Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733479 | 0.87 | PRSS12 (1.00) | PRSS12F10 | |
| SCHEMBL15283100 | 0.85 | PRSS12 (1.00) | PRSS12F10 | |
| SCHEMBL5539074 | 0.84 | PRSS12 (0.70) | PRSS12 | |
| SCHEMBL5538881 | 0.84 | PRSS12 (0.70) | PRSS12F10 | |
| SCHEMBL5535504 | 0.83 | PRSS12 (1.00) | PRSS12 | |
| SCHEMBL4651922 | 0.83 | MAPT (0.78) | PRSS12F10 | |
| SCHEMBL5535843 | 0.83 | PRSS12 (1.00) | PRSS12F10 | |
| SCHEMBL2733946 | 0.83 | PRSS12 (0.77) | PRSS12F10 | |
| SCHEMBL5534180 | 0.81 | PRSS12 (0.71) | PRSS12 | |
| SCHEMBL5538218 | 0.81 | PRSS12 (0.76) | PRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | PRSS12 5/4885F10 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.